NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition. Geneva: World Health Organization; 2009.

Cover of Dengue

Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition.

Show details

METHODOLOGY

These guidelines were written using the following methodology:

1. Writing team

Each chapter was allocated to a WHO coordinator and at least one non-WHO lead writer. The non-WHO lead writers received a small fee for their work. Declarations of interest were obtained from all lead writers and no conflicting interests were declared. The lead writers were chosen because of their expertise in the field and their willingness to undertake the work.

Since this guide has the broad scope of all aspects of prevention and control of dengue, the lead writers were selected for technical expertise in the areas of epidemiology, pathogenesis and transmission, clinical aspects, vector control, laboratory aspects, surveillance and response, and drug and vaccine development.

2. Peer review

All the chapters were submitted to peer review. The peer review groups were determined by the WHO coordinator and the non-WHO lead writers of each chapter. The groups consisted of five or more peer reviewers, who were not paid for their work. Declarations of interest were obtained from all peer reviewers. For those peer reviewers with potential conflicting interests, the interests are declared below.1

For each chapter, the process of reaching agreement on disputed issues differed. For chapters 1, 3, 4 and 6, the comments of the peer reviewers were discussed electronically within the group. Chapter 2 had a larger group whose members met for a consensus group discussion. Chapter 5 required extensive discussion, but consensus was reached without a consensus group meeting. Agreement on the chapter content was reached for all the groups.

3. Use of evidence

For each chapter, items are referenced that (1) provide new data, (2) challenge current practice, (3) describe ongoing research and (4) reflect key developments in knowledge about dengue prevention and control.

Priority was given to systematic reviews when available. Additional literature searches were conducted by the writing teams when items under 1–3 were identified, and references from personal collections of experts were added when appropriate under 4. The writing teams referred to the items under 1–4 in the text, and lists of references were added at the end of each chapter.

Footnotes

1

Declared interests:

Chapter 1. Dr Anne Wilder Smith: principal investigator in dengue vaccine trial starting in 2009.

Chapter 4. Dr Mary Jane Cardosa: shareholder and director of company developing dengue diagnostic tests.

Chapter 6. Dr Robert Edelman: consultant for company involved in dengue vaccine research.

Copyright © 2009, World Health Organization.

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: tni.ohw@sredrokoob). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: tni.ohw@snoissimrep).

Bookshelf ID: NBK143162

Views

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...